On Tuesday, the Food and Drug Administration announced that Covid booster shots will be limited to people over 65 and those ...

In the Phase 2 study of patients with chronic kidney disease, the highest dose of the drug lowered by 86% the levels of ...

In a meta-analysis, both the 200-mg and 400-mg doses were effective, although the 400-mg dose was more effective in those with moderate-to-severe kidney disease.

The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of June 28, 2025, for OLC. Unicycive continues to ...

Pacibekitug showed statistically significant hs-CRP reduction in CKD patients in the phase 2 TRANQUILITY study, establishing ...

New Drug Application (NDA) for hyperphosphatemia in chronic kidney disease patients on dialysis under review by FDA with PDUFA target action date of June 28, 2025; ongoing ...

Study Finds Chemotherapy Antidote Could Improve Recovery After Chemotherapy-Induced Kidney Toxicity Jan. 6, 2025 — An FDA-approved ... Worsening of Chronic Kidney Disease Sep. 12, 2024 ...

Antiperspirants often contain aluminum, which stops your sweat. While some people have concerns about using aluminum, research shows it's generally safe.

The FDA accepted new drug application submissions for twice ... Recent approvals of Jesduvroq/ Duvroq (daprodustat) for ...

The FDA has granted a speedy review of Eli Lilly ... to reduce the risk of renal failure and cardiovascular death in people with chronic kidney disease (CKD). The new indication could unlock ...

The FDA has approved Novavax’s protein-based COVID-19 vaccine, giving some Americans another option besides messenger RNA vaccines to prevent SARS-CoV-2 infection.

The report, to be released Thursday, is expected to identify the key drivers of chronic childhood illness, such as asthma and ...